Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
RESEARCH TOOLSreports
Acrivon Therapeutics, Inc. (ACRV) Stock Price & Analysis
106 Followers
ACRV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.19 - $14.30
Previous Close$9.59
Volume375.35K
Average Volume (3M)777.18K
Market Cap
$296.10M
Enterprise Value$173.28M
Total Cash (Recent Filing)$127.46M
Total Debt (Recent Filing)$4.64M
Price to Earnings (P/E)-3.5
Beta0.86
Next Earnings
May 07, 2024EPS Estimate
-$0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.73
Shares Outstanding30,871,951
10 Day Avg. Volume312,456
30 Day Avg. Volume777,182
Standard Deviation0.27
R-Squared0.04
Alpha-0.00035
Financial Highlights & Ratios
Price to Book (P/B)2.16
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.29K
Enterprise Value/Gross Profit1.29K
Enterprise Value/Ebitda-3.60
Forecast
1Y Price Target
$22.71Price Target Upside136.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Acrivon Therapeutics, Inc. News
PremiumCompany Announcements
Acrivon Therapeutics Reports Breakthrough Results and Solid FinancesBulls Say, Bears Say
Bulls Say
Analyst RatingSKYX Platforms Corp. has been initiated with a Buy rating and a price target of $3.00, indicating a belief in the company's potential for significant share price increase.
Financial PerformanceCullen/Frost Bankers, Inc. experienced a core earnings beat by 3% and has a raised price target to $132 due to strong franchise growth.
Market RecoveryOhmyhome Limited's performance exceeded expectations and the company is well-positioned to benefit from the Singapore housing market recovery.
Bears Say
Clinical Trial ChallengesBladder cancer patient enrollment is lagging, potentially due to recent approval of competitive treatments in the market.
Clinical Trial EnrollmentEnrollment for bladder cancer was lagging compared to ovarian and endometrial cancers.
Financial PerformanceACRV reported a Q4 net loss of $19MM.
---
Ownership Overview
76.32% Insiders
3.01% Mutual Funds
3.50% Other Institutional Investors
17.17% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $3.19 and its highest was $14.30 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is May 07, 2024 which is in 2 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Mar 28, 2024. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.728 by -$0.132.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -$0.84.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 30,875,456 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.728. Following the earnings report the stock price went up 10.681%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Among the largest hedge funds holding Acrivon Therapeutics, Inc.’s share is RA Capital Management. It holds Acrivon Therapeutics, Inc.’s shares valued at 24M.
---
Acrivon Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.71 (136.81% Upside)
$22.71 (136.81% Upside)
Insider Transactions
Bought Shares
Worth $20.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.8%
Last 30 Days ▲ 45.0%
Last 30 Days ▲ 45.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.88%
12-Months-Change
Fundamentals
Return on Equity
-41.41%
Trailing 12-Months
Asset Growth
-23.71%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
---
ACRV Stock 12 Months Forecast
Average Price Target
$22.71
▲(136.81% Upside)
Technical Analysis
Best Analysts Covering ACRV
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
+36.60%
reiterated a buy rating 10 days ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +36.60% per trade.
---